Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 0.0x - 0.0x | 0.0x |
| Historical Pb Multiple | 0.1x - 0.3x | 0.2x |
| Fair Value | C$0.0065 - C$0.0072 | C$0.0069 |
| Upside | -34.7% - -27.8% | -31.3% |
| Benchmarks | - | Full Ticker |
| 4Front Ventures Corp. | - | CNSX:FFNT |
| Harmony Biosciences Holdings, Inc. | - | NasdaqGM:HRMY |
| Evolus, Inc. | - | NasdaqGM:EOLS |
| Tarsus Pharmaceuticals, Inc. | - | NasdaqGS:TARS |
| Bio Essence Corporation | - | OTCPK:BIOE |
| TILT Holdings Inc. | - | NEOE:TILT |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| FFNT | HRMY | EOLS | TARS | BIOE | TILT | |||
| CNSX:FFNT | NasdaqGM:HRMY | NasdaqGM:EOLS | NasdaqGS:TARS | OTCPK:BIOE | NEOE:TILT | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | 61.4% | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 31.3% | 57.3% | -16.5% | 38.7% | -215.1% | -24.5% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -170.4% | 15.2% | -76.7% | -249.9% | -179.4% | -55.1% | ||
| Prior Fiscal Year | -19.8% | 22.1% | -30.5% | -778.9% | NA | -37.6% | ||
| Latest Fiscal Year | -45.9% | 20.4% | -18.9% | -63.2% | -483.3% | -86.2% | ||
| Latest Twelve Months | -46.6% | 23.4% | -22.3% | -31.1% | -243.6% | -100.8% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -237.0% | 15.8% | -478.9% | -38.3% | NA | -136.3% | ||
| Prior Fiscal Year | -64.9% | 29.6% | -666.9% | -69.7% | NM | -67.9% | ||
| Latest Twelve Months | NM | 27.6% | -642.0% | -31.5% | NM | -1121.6% | ||
| Next Fiscal Year | 82.7% | 32.5% | 289.2% | -32.6% | #NUM! | 125.6% | ||
| Two Fiscal Years Forward | -190.2% | 34.8% | -42.5% | -13.9% | 96.0% | 50.6% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 0.0x | 2.7x | 1.6x | 7.7x | 6.4x | 0.0x | ||
| Price / LTM EPS | -0.1x | 11.7x | -7.0x | -24.9x | -2.6x | 0.0x | ||
| Price / Book | -0.1x | 2.7x | -23.3x | 6.9x | -1.2x | 0.0x | ||
| Price / Fwd Book | 0.0x | 2.3x | -15.5x | 14.2x | -1.2x | 0.0x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -23.3x | -0.1x | 6.9x | |||||
| Historical P/B Ratio | 0.1x | 0.2x | 0.3x | |||||
| Selected P/B Multiple | 0.0x | 0.0x | 0.0x | |||||
| (x) Book Value | (62) | (62) | (62) | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | FFNT | HRMY | EOLS | TARS | BIOE | TILT | |
| Value of Common Equity | 3 | 2,121 | 435 | 2,288 | 4 | 3 | |
| (/) Shares Outstanding | 916.4 | 57.5 | 64.7 | 42.2 | 38.0 | 391.3 | |
| Implied Stock Price | 0.00 | 36.87 | 6.73 | 54.21 | 0.10 | 0.01 | |
| FX Conversion Rate to Trading Currency | 0.72 | 1.00 | 1.00 | 1.00 | 1.00 | 0.72 | |
| Implied Stock Price (Trading Cur) | 0.01 | 36.87 | 6.73 | 54.21 | 0.10 | 0.01 | |
| Trading Currency | CAD | USD | USD | USD | USD | CAD | |
| FX Rate to Reporting Currency | 0.72 | 1.00 | 1.00 | 1.00 | 1.00 | 0.72 | |